Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19

Clinical Trial ID NCT04498936

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04498936

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.	N Engl J Med	2020	10.90
2	Nitazoxanide: a new thiazolide antiparasitic agent.	Clin Infect Dis	2005	1.93
3	Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers.	Int J Clin Pharmacol Ther	1996	1.49
4	Nitazoxanide: a first-in-class broad-spectrum antiviral agent.	Antiviral Res	2014	1.32
5	Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level.	J Biol Chem	2009	1.28
6	Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis.	PLoS Pathog	2012	1.05
7	Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation.	Microbiol Mol Biol Rev	2008	0.92
8	Coronaviruses - drug discovery and therapeutic options.	Nat Rev Drug Discov	2016	0.91
9	A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs.	Antiviral Res	2014	0.79
10	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.	Hepatol Int	2016	0.77
11	A review of treatment modalities for Middle East Respiratory Syndrome.	J Antimicrob Chemother	2016	0.76
12	Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.	J Gastroenterol	2017	0.75
13	Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected with HBV.	Gastroenterology	2017	0.75
14	Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.	J Infect Public Health	2016	0.75